Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 11/20 | 0.50 |
| ▸ | ADH1C | P00326 | 8/20 | 0.50 |
| ▸ | ADH1B | P00325 | 2/20 | 0.37 |
| ▸ | ADH4 | P08319 | 2/20 | 0.35 |
| ▸ | ADH7 | P40394 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | EBP | Q15125 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958626 | 0.98 | ADH1A (0.47) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL29955016 | 0.90 | ADH1A (0.37) | ADH1AADH1CADH4ALDH1A1 | |
| SCHEMBL29957210 | 0.82 | ADH1A (0.55) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL29952958 | 0.81 | SLC6A2 (0.39) | ADH1AADH1C | |
| SCHEMBL29952616 | 0.79 | ADH1A (0.52) | ADH1AADH1CADH1BADH4ADH7 | |
| SCHEMBL25121074 | 0.78 | TSHR (0.39) | ADH1AADH1CADH4ALDH1A1 | |
| SCHEMBL8916450 | 0.77 | ADH1A (0.50) | ADH1AADH1CMEN1KMT2A | |
| SCHEMBL612572 | 0.76 | ADH1A (0.50) | ADH1AADH1CMEN1KMT2ASIGMAR1 | |
| SCHEMBL613463 | 0.76 | ADH1A (0.50) | ADH1AADH1CMEN1KMT2ASIGMAR1 | |
| SCHEMBL150343 | 0.76 | ADH1A (0.50) | ADH1AADH1CMEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364033-A1 | COMPOUNDS FOR TREATING VIRUS INFECTIONS | MELETIOS THERAPEUTICS (FR) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364033-A1 | COMPOUNDS FOR TREATING VIRUS INFECTIONS | ACE, HAVCR2, FURIN | ADH1A 197/4885ADH1C 462/4885ADH1B 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.